Faculty Articles

Title

Flibanserin (Addyi): The First FDA-Approved Treatment for Female Sexual Interest/Arousal Disorder in Premenopausal Women

Publication Title

P&T (Pharmacy & Therapeutics)

Volume

42

Issue

4

Publication Date / Copyright Date

4-1-2017

First Page

237

Last Page

241

Publisher

MediMedia

Abstract

Female sexual interest/arousal disorder (FSIAD) is a newly defined clinical diagnosis that appears in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5).1 The diagnosis was previously listed as hypoactive sexual desire disorder (HSDD) in DSM-4 and as inhibited sexual desire disorder in DSM-3. References to the condition prior to 2013 (and even afterward), including research studies, often refer to the condition as HSDD.

Disciplines

Medicine and Health Sciences | Pharmacy and Pharmaceutical Sciences

Keywords

arousal, females, hypoactive sexual desire disorder (HSDD), menopause, pre-menopause, sexual interest

Peer Reviewed

Find in your library

Share

 
COinS